Parabilis Medicines (NASDAQ:PBLS – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Parabilis Medicines to related businesses based on the strength of its institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.
Insider and Institutional Ownership
47.8% of shares of all “Biotechnology” companies are held by institutional investors. 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Parabilis Medicines and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Parabilis Medicines | $148,000.00 | -$145.89 million | -13.13 |
| Parabilis Medicines Competitors | $755.61 million | $11.71 million | -18.64 |
Parabilis Medicines’ competitors have higher revenue and earnings than Parabilis Medicines. Parabilis Medicines is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Parabilis Medicines and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Parabilis Medicines | N/A | -73.69% | -25.40% |
| Parabilis Medicines Competitors | -12,224.09% | -202.33% | -31.23% |
Analyst Recommendations
This is a summary of current ratings and price targets for Parabilis Medicines and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Parabilis Medicines | 1 | 1 | 6 | 1 | 2.78 |
| Parabilis Medicines Competitors | 9923 | 15313 | 45678 | 1602 | 2.54 |
Parabilis Medicines presently has a consensus price target of $40.80, indicating a potential upside of 45.87%. As a group, “Biotechnology” companies have a potential upside of 128.06%. Given Parabilis Medicines’ competitors higher probable upside, analysts clearly believe Parabilis Medicines has less favorable growth aspects than its competitors.
Summary
Parabilis Medicines beats its competitors on 7 of the 12 factors compared.
About Parabilis Medicines
Parabilis Medicines is a clinical-stage biopharmaceutical company developing medicines for diseases driven by proteins that have been difficult to target with conventional drugs. Its research focuses on macrocyclic peptides designed to address challenging protein interactions, including targets relevant to cancer. The company uses its proprietary Helicon platform to design these peptide-based drug candidates. Parabilis is based in Cambridge, Massachusetts, and was formerly known as Peptone. Parabilis was founded by Gregory Verdine, who serves as the company’s chief executive officer.
Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
